Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Alpelisib Combo Promising in PIK3CA-Altered, Heavily Pretreated Breast Cancer
The combination of the alpha-specific PI3K inhibitor alpelisib (BYL719) and fulvestrant (Faslodex) demonstrated promising early efficacy and mild toxicity in heavily pretreated postmenopausal women with ER-positive metastatic breast cancer.
Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBC
March 12th 2016Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation, time to next treatment, and had a favorable safety profile compared with paclitaxel.
Dr. Mittendorf on Nelipepimut-S Plus GM-CSF in Breast Cancer
March 11th 2016Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses a clinical trial examining nelipepimut-S plus GM-CSF vaccine therapy as a treatment for patients with breast cancer.
Dr. Symmans on Moon Shots Program for Patients With TNBC
March 11th 2016William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.
Dr. Schoenfeld on Immunologic Effects of Chemotherapy and Radiation in Head and Neck Cancer
Jonathan D. Schoenfeld, MD, MPH, physician, assistant professor of Radiation Oncology, Harvard Medical School, Dana Farber Cancer Center on the immunologic effects of chemotherapy and radiation in head and neck cancer.
Dr. Randal Weber on Future Treatment Approaches for Patients With Melanoma
March 1st 2016Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.
Dr. Frakes on Managing Late Toxicities Associated With Treatment for HPV+ Oropharyngeal SCC
February 26th 2016Jessica Frakes, MD, assistant professor of Radiation Oncology, Department of Radiation Oncology, Moffitt Cancer Center, discusses management of toxicities associated with treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.
Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC
February 25th 2016Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).
Pazopanib/Cetuximab Combo Shows Promising Efficacy in Advanced HNSCC
February 23rd 2016The combination of pazopanib (Votrient) and cetuximab (Erbitux) showed a disease control rate of 77% in patients with recurrent or metastatic head and neck squamous cell carcinoma, including patients with cetuximab- or platinum-resistant disease.
Cetuximab Improves Long-Term Control in HPV-Negative Head and Neck Cancer
February 22nd 2016Among patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis, adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control.
Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer
February 22nd 2016James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.
Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients With DTC
February 20th 2016Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).
Dr. Zevallos on Molecular Profile of HPV-Positive Oropharyngeal SCC Stratified by Smoking Status
February 20th 2016Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.
Dr. Ferris on Potential of Nivolumab in Head and Neck Cancer
February 19th 2016Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab's potential as a treatment of patients with head and neck cancer, as reported in the CheckMate-141 study.
Social Isolation, Financial Toxicity Equate to Risk Factors in Head and Neck Cancer
Patients with locally advanced head and neck cancer should be screened for social isolation and financial hardship, as these factors play a role in their ability to stay on medication, minimize hospital stays, and achieve optimal health outcomes.
HPV+ Oropharyngeal Cancer Recurrence Typically Detected Within 6 Months of Treatment
February 19th 2016In patients treated with definitive radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma, most recurrences can be detected via imaging at 3 months and physical examinations during the first 6 months after treatment.
